【摘要】 目的探讨依达拉奉治疗对脑梗死患者血清Aβ(1-40)、Aβ(1-42)的影响。方法选择脑梗死患者64例,将其分为依达拉奉组及对照组,每组32例,依达拉奉组给予静脉滴注依达拉奉30mg/日,每日2次,共治疗14天;对照组不使用依达拉奉,其他治疗相同。两组患者分别于治疗前、治疗后3周、治疗后6周抽取静脉血进行Aβ(1-40)、Aβ(1-42)水平检测,将检测结果进行统计学分析。结果治疗前依达拉奉组血清Aβ(1-40)为1.87±0.39,对照组血清Aβ(1-40)为1.83±0.41,两组间无显著差异(P=0.691)。治疗前依达拉奉组血清Aβ(1-42)为1.43±0.26,对照组血清Aβ(1-42)为1.45±0.29(P=0.675),治疗后3、6W,依达拉奉组Aβ(1-40)水平逐步降低(1.79±0.35 vs 1.34±0.21,P<0.05)。依达拉奉组Aβ(1-42)于治疗后3W升高(1.61±0.32,P<0.05)。对照组Aβ(1-40)和Aβ(1-42)水平无显著改变(P>0.05)。治疗前两组Aβ(1-40)/Aβ(1-42)比率无差异(依达拉奉组1.365,对照组1.314,P=0.582),治疗后3、6W依达拉奉组Aβ(1-40)/Aβ(1-42)比率逐步降低(1.17,0.89),对照组Aβ(1-40)/Aβ(1-42)比率于治疗后3W明显增高(1.58,P=0.048),其后下降,但仍大于治疗前水平。结论依达拉奉可以降低急性脑梗死后血清Aβ(1-40)水平,降低血清Aβ(1-40)/Aβ(1-42)比率。更多还原

【Abstract】 Objective To investigate the effects of edaravone on serum Aβ1-40 and Aβ1-42 in patients with acute cerebral infarction.Methods 64 patients with acute cerebral infarction were enrolled within 48 h of onset.Enrolled patients were randomized into edaravone and control groups.Edaravone was infused at a dose of 30 mg,twice daily for 14 days,and control received similar treatment except edaravone infusion.Results There were no significant difference of serum levels of Aβ1-40 and Aβ1-42 before treatment.Three and six weeks after treatment,the serum levels of Aβ1-40 increased gradually in control group.Aβ1-40 level also increased in edaravone group 3 weeks after treatment also,but the level decreased 6 weeks after treatment.The levels of Aβ1-42 in edaravone group were increased at the point of 3 weeks after treatment,and then begin to decline,but at the point of 6 weeks after treatment,which was higher than that of the baseline.The serum levels of beta-amyloids 1-42 in the control group was decreased significantly 3 weeks after treatment and then increased slightly.The ratio of Aβ1-40/ Aβ1-42 decreased gradually 3 weeks after treatment,but it increased significantly at the time of 3W after treatment.Conclusion Edaravone may decrease serum Aβ1-40 and ratio of Aβ1-40/ Aβ1-42 in patients with acute cerebral infarction.更多还原